Biogen Inc.
Biogen Completes Acquisition of Apellis Pharmaceuticals
Summary
On May 14, 2026, Biogen Inc. announced the successful completion of its acquisition of Apellis Pharmaceuticals, Inc. for approximately $5.3 billion, excluding related fees and expenses and potential contingent value rights (CVR) payments. The acquisition, which was financed through a combination of cash and borrowings, includes the issuance of CVRs that could entitle holders to up to an additional $582 million if certain sales milestones are achieved. Additionally, Biogen entered into a new $2 billion credit agreement to fund the acquisition. The transaction is expected to be accretive to Biogen's non-GAAP diluted EPS in 2027 and materially increase its non-GAAP EPS compound annual growth rate through the end of the decade.
Profitelligence Alerts
Get alerts for BIIB
Be first to know when Biogen Inc. files with the SEC.
Filing Categories
Advertisement
About Biogen Inc.
Biogen Inc. is a globally recognized biotechnology company committed to discovering, developing, and delivering innovative therapies for neurological diseases. With a focus on serious medical conditions, Biogen creates therapies aimed at treating conditions like multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company invests heavily in research and development to pioneer treatments that improve patients' quality of life and addresses critical unmet medical needs. Biogen's influence spans various therapeutic areas in the healthcare sector, making notable strides in both neurodegenerative and rare diseases. The company's portfolio includes a range of biologics, gene therapy, and small molecule drugs, highlighting its strategic diversity. As a prominent player within the biopharmaceutical industry, Biogen collaborates with academic institutions, research organizations, and other biotech firms to enhance its research pipeline and bring new solutions to market. Biogen's role in the financial markets is underscored by its contributions to healthcare innovation and its impact on global health outcomes. Headquartered in Cambridge, Massachusetts, Biogen continues to leverage its scientific expertise and industry alliances to remain at the forefront of biotechnology, influencing both investors and the broader medical community.
Official SEC Documents
Advertisement